CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback

Company Overview - CorMedix Inc. is a commercial-stage biopharmaceutical company founded on July 28, 2006, and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapies to prevent and treat infections, particularly with its product DefenCath aimed at patients undergoing hemodialysis [4]. Share Repurchase Program - CorMedix announced a share repurchase program authorizing up to $75 million in common stock buybacks, effective through December 31, 2027. This decision reflects the company's confidence in its balance sheet strength, operating performance, and expected future cash flow generation [1]. - The company expects to begin share repurchases as early as the first quarter of 2026. As of December 31, 2025, CorMedix reported approximately $150 million in cash and cash equivalents and about 79.3 million shares outstanding, indicating capacity to execute the program alongside ongoing business and clinical development priorities [1]. Insider Activity - In January, CorMedix's Executive Vice President and General Manager of Healthcare, Janet Dillione, sold 10,000 shares for proceeds of $68,800. While this transaction is modest in absolute dollar terms, it represents a round-lot sale by a senior executive overseeing a core business segment, which is often monitored closely by investors in smaller-cap biotech companies [3].